Answers are grounded in this paper and cite their sources.
Background: Lumateperone is an approved treatment for bipolar depression with a low reported risk of treatment-emergent mania. However, real-world evidence remains limited. Cases: We describe three adults with bipolar depression who developed manic symptoms within 10-14 days of initiating lumateperone 42 mg/day. Young Mania Rating Scale scores ranged from 26 to 29. Alternative causes were excluded, symptoms resolved after discontinuing lumateperone and optimizing mood stabilizers, and Naranjo scores (7-8) indicated a probable drug association. Conclusion: Lumateperone may precipitate mania in susceptible individuals, highlighting the need for close monitoring during the early treatment period.
No takes yet. Share an insight, caveat, or question.
Mudgal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: